Summary
Eighteen patients with metastatic renal cell carcinoma, who were treated by vaccines for active specific immunotherapy, also completed skin testing with autologous tumor cells, both prior to and following vaccine treatment. All patients have now been followed for more than 5 years. Ten patients who remained skin-test-negative following treatment had no clinical responses, and all had expired by 22 months. Eight patients became skin-test-positive; three of these had clinical regressions and three remain alive after more than 69 months. The survival times of the skin-test-positive group were significantly superior to those of the skin-test-negative group. The results suggest that skin testing with autologous tumor cells may accurately identify those patients who have acquired antigenspecific cell-mediated antitumor immunity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Askenase PW, Hayden BJ, Gershon RK (1975) Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 141: 697
Berd D, Mastrangelo MJ, Engstrom PF, Paul A, Maguire H (1982) Augmentation of the human immune response by cyclophosphamide. Cancer Res 42: 4862
Berd D, Maguire HC, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46: 2572
Burdick JF, Wells Jr SA, Herberman RB (1975) Collective review: immunologic evaluation of patients with cancer by delayed hypersensitivity reactions. Surg Gynecol Obstet 141: 779
Hoover HC, Surdyke MG, Dangel RB, Peters LC, Hanna MG (1984) Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: bacillus Calmette-Guérin vaccine. Cancer Res 44: 1671
Hoover HC, Surdyke MG, Dangel RB, Peters LC, Hanna MG (1985) Prospectively randomized trial of adjuvant active-specific immunotherapy for colorectal cancer. Cancer 55: 1236
McCune CS, Schapira DV, Henshaw EC (1981) Specific immunotherapy for advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 47: 1984
McCune CS, O'Donnell RW, Horan PK, Budd HS, Spennacchio JL, Chuang C, Henshaw EC (1982) Antitumor immunity induced by hybrid murine tumor cells: requirements for optimal immunization. J Natl Cancer Inst 69: 647
McCune CS, Henshaw EC, Marquis DM, Sahasrabudhe DM, Leary JF, O'Donnell RW (1987) Human hybrid tumor cells: observations on their production and clinical effects. J Biol Response Mod 6: 130
Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S (1988) Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48: 5883
Sahasrabudhe DM, deKernion JB, Pontes JE, Ryan DH, O'Donnell RW, Marquis DM, Mudholkar GS, McCune CS (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Mod 5: 58
Sokol JE (1975 Measurement of delayed skin test responses (letter). N Engl J Med 29: 501
Author information
Authors and Affiliations
Additional information
Supported by U.S. Public Health Service grants CA30 573, CA27 625, and by a gift from Mr. Joseph Hanna
Rights and permissions
About this article
Cite this article
McCune, C.S., O'Donnell, R.W., Marquis, D.M. et al. Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 32, 62–66 (1990). https://doi.org/10.1007/BF01741726
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01741726